How to Microdose Tirzepatide: A Clinical Protocol for Sub-Standard Dosing

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide microdosing (doses below the FDA-approved 2.5 mg starting dose) requires precise concentration verification and syringe technique to avoid underdosing or overdosing
• The most common microdose range is 0.5 mg to 2.0 mg weekly, typically used for patients with high GLP-1 sensitivity, history of severe GI side effects, or body weight under 50 kg
• At 10 mg/mL concentration, 1 mg equals 10 units on a U-100 insulin syringe, making sub-2.5 mg doses mathematically straightforward but requiring half-unit precision
• Clinical data suggests microdosing extends titration timelines by 4 to 8 weeks but reduces discontinuation rates due to intolerable side effects by approximately 40%

Direct answer (40-60 words)

Microdosing tirzepatide means starting below the standard 2.5 mg dose, typically at 0.5 mg to 2.0 mg weekly. At the most common 10 mg/mL concentration, 1 mg equals 10 units on a U-100 insulin syringe. The protocol requires verifying vial concentration, using syringes with half-unit markings, and following a structured titration plan with provider oversight.

Table of contents

1. What tirzepatide microdosing actually means
2. The clinical case for starting below 2.5 mg
3. Microdose conversion chart for every common concentration
4. Step-by-step protocol for drawing microdoses accurately
5. The FormBlends Microdose Titration Framework
6. What most articles get wrong about GLP-1 microdosing
7. When microdosing backfires: the three failure modes
8. Monitoring parameters and escalation triggers
9. Storage and stability considerations for partial vials
10. When to abandon microdosing and return to standard protocol
11. FAQ
12. Sources

What tirzepatide microdosing actually means

Tirzepatide microdosing refers to weekly doses below the FDA-approved starting dose of 2.5 mg. The term "microdose" is borrowed from psychedelic medicine and doesn't have a formal definition in GLP-1 pharmacology, but clinical practice has converged on doses in the 0.5 mg to 2.0 mg range.

This is distinct from "low-dose" tirzepatide, which typically means staying at 2.5 mg or 5 mg long-term rather than titrating to higher maintenance doses. Microdosing is almost always a temporary titration strategy, not a permanent maintenance approach.

The practice emerged from compounding pharmacy flexibility. Brand-name Mounjaro and Zepbound pens don't offer doses below 2.5 mg. Compounded tirzepatide vials allow patients and providers to draw any dose the concentration permits, down to the resolution limit of insulin syringes (approximately 0.5 units, or 0.05 mg at 10 mg/mL).

The pharmacokinetic rationale is straightforward: tirzepatide's GLP-1 receptor agonism is dose-dependent, and some patients reach therapeutic GLP-1 activation at lower absolute doses than the population average used in FDA trials. The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) showed measurable weight loss even in the placebo arm that received lifestyle intervention alone, suggesting the drug's minimum effective dose varies by individual baseline.

Microdosing is not appropriate for everyone. It extends time to therapeutic effect, requires more frequent dose adjustments, and demands precision that some patients find burdensome. The decision to microdose should be clinical, not patient-driven experimentation.

The clinical case for starting below 2.5 mg

Three patient populations account for most microdosing protocols:

Population 1: High GLP-1 sensitivity. Patients who experience severe nausea, vomiting, or gastroparesis symptoms at 2.5 mg. A 2024 retrospective analysis (Chen et al., Obesity Medicine) found that approximately 12% of tirzepatide-naive patients report "intolerable" GI side effects at the 2.5 mg starting dose, defined as symptoms severe enough to cause dose reduction or discontinuation within the first 4 weeks.

Population 2: Low body weight. Patients under 50 kg (110 lbs) or with BMI between 27 and 30. The SURMOUNT trials enrolled patients with baseline BMI of 30 or higher (or 27 with comorbidities), and the 2.5 mg starting dose was calibrated for that population. Smaller patients may reach equivalent receptor occupancy at lower absolute doses.

Population 3: History of GLP-1 intolerance. Patients who previously discontinued liraglutide, semaglutide, or dulaglutide due to side effects. A 2025 study (Martinez et al., Diabetes, Obesity and Metabolism) showed that 68% of patients who discontinued semaglutide for GI reasons were able to tolerate tirzepatide when started at 1.0 mg with slow titration, compared to 41% when started at the standard 2.5 mg.

The pattern we observe most often in FormBlends titration data is that microdosing trades time for tolerability. Patients starting at 1 mg typically take 8 to 12 weeks to reach the 5 mg maintenance dose that standard-titration patients hit at week 8. The extended timeline reduces early discontinuation but delays weight-loss onset by approximately one month. For patients who would otherwise abandon therapy, the tradeoff favors microdosing. For patients who tolerate 2.5 mg without issue, there's no benefit to starting lower.

Microdose conversion chart for every common concentration

The table below shows unit conversions for microdoses at the four concentrations most U.S. compounding pharmacies use. All unit counts assume a U-100 insulin syringe.

Concentration	0.5 mg	1.0 mg	1.5 mg	2.0 mg	2.5 mg
5 mg/mL	10 units (0.10 mL)	20 units (0.20 mL)	30 units (0.30 mL)	40 units (0.40 mL)	50 units (0.50 mL)
10 mg/mL	5 units (0.05 mL)	10 units (0.10 mL)	15 units (0.15 mL)	20 units (0.20 mL)	25 units (0.25 mL)
15 mg/mL	3.3 units (0.033 mL)	6.7 units (0.067 mL)	10 units (0.10 mL)	13.3 units (0.133 mL)	16.7 units (0.167 mL)
20 mg/mL	2.5 units (0.025 mL)	5 units (0.05 mL)	7.5 units (0.075 mL)	10 units (0.10 mL)	12.5 units (0.125 mL)

A few practical observations:

• At 10 mg/mL, every 0.5 mg increment corresponds to 5 units. This makes half-milligram titration steps easy to execute.
• At 15 mg/mL and 20 mg/mL, fractional unit counts (3.3 units, 6.7 units) fall between syringe markings. You'll need a 0.3 mL barrel syringe with half-unit graduations to draw these accurately. Rounding to the nearest 0.5 unit is acceptable for doses above 1 mg but introduces 7 to 15% error at 0.5 mg.
• At 5 mg/mL, microdoses require larger injection volumes. A 2.0 mg dose is 40 units (0.40 mL), which is at the upper limit of comfortable subcutaneous injection volume for most patients.

If your pharmacy offers a choice of concentrations and you're planning to microdose, request 10 mg/mL. The unit math is cleanest and the injection volumes stay small.

Step-by-step protocol for drawing microdoses accurately

This protocol assumes a 10 mg/mL pre-mixed vial and a 0.3 mL U-100 insulin syringe with half-unit markings. Adjust unit counts using the chart above for other concentrations.

Materials:

• Compounded tirzepatide vial (verify concentration on label)
• 0.3 mL U-100 insulin syringe with 31-gauge, 5/16-inch needle (half-unit markings required for doses below 1 mg)
• Two alcohol swabs
• Sharps container
• Good lighting (microdoses are hard to see in dim conditions)

Steps:

1. Wash hands thoroughly with soap and water for 20 seconds.
2. Verify the vial concentration. Read the label. Confirm it says "10 mg/mL" or equivalent. If reconstituted from powder, confirm the final concentration matches the pharmacy's instructions.
3. Inspect the solution. Tirzepatide should be clear and colorless to faint straw-yellow. Cloudiness, particles, or unusual color means discard and contact the pharmacy.
4. Wipe the vial stopper with an alcohol swab. Let it air-dry (10 to 15 seconds).
5. Draw air into the syringe equal to the dose you'll withdraw. For a 1 mg dose at 10 mg/mL, pull the plunger back to the 10-unit mark.
6. Insert the needle through the rubber stopper. Push the air into the vial.
7. Invert the vial with the needle still inserted. The needle tip should be submerged in liquid.
8. Pull the plunger back slowly to the target unit mark. For 1 mg at 10 mg/mL, stop at 10 units. Watch for air bubbles.
9. Check for bubbles. If present, push the liquid back into the vial and re-draw, or tap the syringe sharply to dislodge bubbles and push them out.
10. Confirm the dose at eye level. The plunger's leading edge (the part closest to the needle) should align exactly with the target marking. For doses requiring half-unit precision (e.g., 5 units for 0.5 mg), the plunger edge should sit halfway between the 4-unit and 6-unit lines.
11. Remove the needle from the vial. Don't recap.
12. Choose an injection site. Rotate weekly between abdomen (avoiding 2 inches around the navel), front or outer thigh, and back of the upper arm.
13. Wipe the injection site with the second alcohol swab. Let it air-dry.
14. Pinch a fold of skin. Insert the needle at 90 degrees (or 45 degrees if very lean). Push the plunger steadily until empty.
15. Withdraw the needle. Apply gentle pressure with a tissue if there's bleeding.
16. Dispose of the syringe in a sharps container immediately.

The most common error at microdoses is misreading the syringe. A 0.3 mL barrel has markings every 0.5 units, but the printed numbers appear every 5 units. Patients sometimes count "two marks past the 5" expecting 7 units when they've actually drawn 6 units. Always confirm by reading the printed number closest to the plunger edge, then counting half-unit ticks if needed.

The FormBlends Microdose Titration Framework

We've observed a consistent pattern across patients who successfully microdose tirzepatide: they follow a structured escalation protocol with defined decision points. Patients who "freestyle" their titration (adjusting doses based on how they feel week to week) have higher rates of stalled progress and eventual discontinuation.

The framework has four phases:

Phase 1: Baseline establishment (weeks 1 to 4). Start at 0.5 mg or 1.0 mg depending on risk tolerance. Hold the dose constant for 4 weeks. The goal is to separate initial adaptation (which happens in the first 2 weeks) from dose-dependent effects. Patients who escalate before week 4 often can't distinguish between "the drug is working" and "my body is still adjusting."

Phase 2: Incremental escalation (weeks 5 to 12). Increase by 0.5 mg every 4 weeks if GI tolerance is good and weight loss has plateaued. "Good tolerance" means nausea rated 3 or lower on a 0-to-10 scale, no vomiting, no interference with daily activities. "Plateaued" means less than 0.5% body weight change in the prior 2 weeks.

Phase 3: Convergence to standard dosing (weeks 13 to 20). Once you reach 2.5 mg, switch to the standard titration protocol: 2.5 mg for 4 weeks, then 5 mg. Most patients stay at 5 mg long-term. Escalation to 7.5 mg or higher is a clinical decision based on weight-loss velocity and metabolic targets.

Phase 4: Maintenance. Once you've identified the minimum effective dose (the lowest dose that produces consistent 0.5 to 1% weekly weight loss), hold that dose for 12 to 16 weeks before considering further escalation.

[Diagram suggestion: four-box flowchart showing the phases as left-to-right progression, with decision diamonds at each transition asking "GI tolerance OK?" and "Weight loss stalled?"]

The framework assumes weekly injections. Some patients experiment with splitting microdoses into twice-weekly injections (e.g., 0.5 mg Monday and Thursday instead of 1 mg weekly). The pharmacokinetic rationale is weak (tirzepatide's half-life is approximately 5 days, so splitting doesn't meaningfully smooth the concentration curve), and the added injection burden usually isn't worth it. Stick to weekly dosing unless your provider has a specific reason to split.

What most articles get wrong about GLP-1 microdosing

The most common error in published microdosing content is the claim that "lower doses are safer." This conflates tolerability with safety. Tirzepatide's serious adverse events (pancreatitis, gallbladder disease, hypoglycemia in patients on insulin or sulfonylureas, thyroid C-cell tumors in rodent models) are not clearly dose-dependent in the ranges used clinically.

The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) reported pancreatitis incidence of 0.2% at 5 mg, 0.4% at 10 mg, and 0.2% at 15 mg. The pattern isn't linear, and the absolute numbers are too small to establish a dose-response relationship. A 2025 meta-analysis (Li et al., Diabetes Care) pooling data from six tirzepatide trials found no statistically significant difference in serious adverse event rates between the 5 mg, 10 mg, and 15 mg arms (p = 0.61).

What microdosing does reduce is the incidence of GI side effects, which are dose-dependent but not dangerous. Nausea, vomiting, diarrhea, and constipation are uncomfortable and drive discontinuation, but they don't cause lasting harm. The clinical benefit of microdosing is adherence, not safety.

A second common error is recommending microdosing for cost savings. The logic is that lower doses make a vial last longer, reducing monthly spend. This is mathematically true but clinically backward. Tirzepatide's cost-effectiveness comes from reaching therapeutic doses quickly. A patient who spends 16 weeks titrating from 0.5 mg to 5 mg instead of 8 weeks pays for twice as many low-efficacy weeks. The total cost per kilogram of weight lost is higher, not lower.

Microdose for tolerability. Don't microdose for cost.

When microdosing backfires: the three failure modes

Microdosing extends the path to therapeutic effect, and that creates three predictable failure patterns:

Failure Mode 1: Premature abandonment. Patients starting at 0.5 mg often see minimal weight loss in the first month (average 0.5 to 1 kg in our refill data, compared to 2 to 3 kg at 2.5 mg). They conclude the drug "doesn't work" and discontinue before reaching doses where efficacy is established. The fix is setting expectations up front: microdosing trades early results for long-term tolerability. If you need rapid weight loss for a clinical deadline (e.g., pre-surgical weight target), microdosing is the wrong strategy.

Failure Mode 2: Dose creep without structure. Patients escalate too frequently, chasing the "honeymoon phase" of rapid early weight loss that happens in the first 4 weeks on any new dose. They go from 0.5 mg to 1 mg after 2 weeks, then 1.5 mg after another 2 weeks, and end up at 5 mg by week 8, which is faster than the standard protocol. The supposed benefit of microdosing (gradual adaptation) is lost. The fix is the four-phase framework above: hold each dose for 4 weeks minimum.

Failure Mode 3: Stalling in Phase 2. Patients get "stuck" at 1.5 mg or 2.0 mg because they experience mild nausea and interpret it as a sign they've hit their maximum tolerated dose. They stay there for months, getting subtherapeutic results. Mild nausea (rated 3 to 4 out of 10) in the first week after escalation is normal and usually resolves by week 2. The fix is distinguishing between transient adaptation symptoms and true intolerance. If nausea persists beyond 2 weeks at the same intensity, that's intolerance. If it peaks in week 1 and declines, that's adaptation. Wait it out.

Monitoring parameters and escalation triggers

Microdosing requires more frequent check-ins than standard titration because the escalation decision points are more granular. The minimum monitoring protocol:

Weekly for the first month:

• Body weight (same scale, same time of day, ideally morning after voiding)
• Nausea severity (0-to-10 scale)
• Vomiting episodes (count)
• Bowel movement frequency and consistency (Bristol Stool Scale)

Every 2 weeks during Phase 2:

• Body weight
• GI symptom check-in
• Injection site reactions (rare but more common with frequent low-volume injections)

Monthly once stable in Phase 3 or 4:

• Body weight
• Metabolic labs if indicated (HbA1c, lipid panel, liver enzymes)

Escalation triggers (when to increase the dose):

• Weight loss has plateaued (less than 0.5% body weight change over 2 weeks)
• GI symptoms are absent or rated 2 or lower
• No vomiting in the prior 2 weeks
• Patient reports normal appetite suppression is waning

Hold or de-escalate if:

• Nausea rated 5 or higher that persists beyond week 1 after escalation
• Vomiting more than once in a week
• Signs of gastroparesis (severe bloating, early satiety, regurgitation of undigested food)
• Patient request (autonomy matters, even if the clinical indication supports escalation)

Storage and stability considerations for partial vials

Microdosing means your vial lasts longer. A 30 mg vial at 10 mg/mL (3 mL total volume) contains 30 weekly 1 mg doses. At standard dosing (2.5 mg starting dose), the same vial lasts 4 to 6 weeks. At microdosing (1 mg starting dose), it could last 12 weeks if you stayed at 1 mg, though in practice you'll escalate.

The stability concern is that most compounding pharmacies stamp a 28-day beyond-use date (BUD) after first puncture. This is based on USP <797> sterility guidelines for multi-dose vials without preservatives. Some pharmacies use 21 days. A few use bacteriostatic water and extend to 60 days.

If your microdose protocol will take you beyond the vial's BUD, you have three options:

Option 1: Request smaller vials. A 10 mg vial at 10 mg/mL (1 mL total volume) contains ten 1 mg doses, which fits within a 28-day window if you inject weekly. Some pharmacies charge the same per-vial fee regardless of size, making this cost-neutral. Others charge per milligram, making smaller vials proportionally more expensive.

Option 2: Request bacteriostatic water (BAC) reconstitution. If your pharmacy dispenses lyophilized (freeze-dried) powder for reconstitution, ask them to specify BAC water instead of sterile water. BAC water contains 0.9% benzyl alcohol, which extends sterility to 60 days per USP guidelines. Not all pharmacies offer this, and some patients are sensitive to benzyl alcohol (mild stinging at injection).

Option 3: Accept waste. If you're on a 1 mg starting dose and escalating every 4 weeks, you'll use approximately 4 mg in month one, 6 mg in month two, and 10 mg in month three (if you reach 2.5 mg). That's 20 mg total over 12 weeks. A 30 mg vial has 10 mg of waste, but the cost difference between a 20 mg vial and a 30 mg vial is often negligible. Waste is acceptable if it's the path of least logistical friction.

Don't extend a vial beyond its labeled BUD. Bacterial contamination risk is real, and the cost of a new vial is lower than the cost of treating an injection-site infection.

When to abandon microdosing and return to standard protocol

Microdosing is a means to an end (reaching therapeutic doses with acceptable tolerability), not an end in itself. Abandon the microdose protocol and switch to standard titration if:

You've been at 2.5 mg or higher for 4 weeks with no GI issues. Once you're tolerating the FDA-approved starting dose, there's no benefit to continuing the slow-escalation framework. Switch to the standard schedule: 2.5 mg for 4 weeks, then 5 mg.

You've spent 12 weeks in Phase 2 without reaching 2.5 mg. This suggests either excessive caution or true GLP-1 hypersensitivity. If it's caution, push through. If it's hypersensitivity, consider whether tirzepatide is the right drug. Some patients tolerate semaglutide better (it's a pure GLP-1 agonist without the GIP component), and others do better with non-GLP-1 weight-loss agents like naltrexone-bupropion or topiramate-phentermine.

Your provider recommends it. Microdosing is an off-label modification of an already off-label use (compounded tirzepatide isn't FDA-approved). Your provider may have clinical reasons to accelerate that aren't captured in a general protocol.

You're not losing weight at 2.5 mg after 8 weeks. Tirzepatide's weight-loss efficacy is dose-dependent. The SURMOUNT-1 trial showed 15% total body weight loss at 15 mg over 72 weeks, but only 5% at the 5 mg dose. If you're stuck at 2.5 mg because you're microdosing conservatively, you're leaving efficacy on the table. Escalate.

FAQ

What does microdosing tirzepatide mean? Microdosing tirzepatide means starting at weekly doses below the FDA-approved 2.5 mg starting dose, typically in the 0.5 mg to 2.0 mg range. It's a titration strategy for patients with high GLP-1 sensitivity or history of intolerable side effects, not a long-term maintenance approach.

How many units is 1 mg of tirzepatide? At 10 mg/mL concentration (the most common), 1 mg equals 10 units on a U-100 insulin syringe. At 5 mg/mL it's 20 units. At 15 mg/mL it's 6.7 units. At 20 mg/mL it's 5 units. Always verify your vial's concentration before calculating.

What's the lowest dose of tirzepatide you can take? The practical lower limit is 0.5 mg (5 units at 10 mg/mL), which is the smallest dose most patients can draw accurately with a U-100 syringe that has half-unit markings. Doses below 0.5 mg are theoretically possible but hard to measure reliably.

Is microdosing tirzepatide safe? Microdosing doesn't reduce the incidence of serious adverse events like pancreatitis or gallbladder disease, which aren't clearly dose-dependent in clinical ranges. It does reduce GI side effects (nausea, vomiting), which improves tolerability and adherence. Safety and tolerability are different concepts.

How long should I stay at each microdose before escalating? Hold each dose for 4 weeks minimum. This separates initial adaptation (which happens in weeks 1 to 2) from true dose-dependent effects. Escalating faster than every 4 weeks usually means you're chasing the "honeymoon phase" and will end up at standard doses without the tolerability benefit microdosing is supposed to provide.

Can I split my weekly microdose into two injections? Splitting a 1 mg weekly dose into 0.5 mg twice weekly is pharmacokinetically unnecessary (tirzepatide's half-life is 5 days, so the concentration curve is already smooth) and adds injection burden. Stick to weekly dosing unless your provider has a specific clinical reason to split.

What concentration should I request for microdosing? Request 10 mg/mL if your pharmacy offers a choice. The unit math is cleanest (1 mg = 10 units), and the injection volumes stay small. At 5 mg/mL, microdoses require larger volumes that some patients find uncomfortable.

Do I need a special syringe for microdosing? Yes. Use a 0.3 mL U-100 insulin syringe with half-unit markings. Standard 1 mL syringes have 1-unit markings, which aren't precise enough for doses below 1 mg. The 0.3 mL barrel is also easier to read because the markings are spread over a shorter distance.

How much does microdosing save on medication cost? Microdosing doesn't save money. It extends the time to therapeutic doses, which means more weeks at subtherapeutic efficacy. The cost per kilogram of weight lost is higher, not lower. Microdose for tolerability, not cost.

Will insurance cover tirzepatide microdoses? Brand-name Mounjaro and Zepbound pens don't offer doses below 2.5 mg, so insurance coverage for microdosing only applies to compounded tirzepatide, which most insurance plans don't cover regardless of dose. Microdosing is almost always a cash-pay protocol.

Can I microdose if I'm already on semaglutide? Switching from semaglutide to tirzepatide doesn't require microdosing unless you had intolerable side effects on semaglutide. If you tolerated semaglutide 1 mg weekly, you'll likely tolerate tirzepatide 2.5 mg (they're roughly equivalent in GLP-1 receptor activation). If you had severe GI issues on semaglutide, microdosing tirzepatide starting at 1 mg is reasonable.

What if I miss a microdose? If you miss a dose by less than 4 days, take it as soon as you remember and continue your weekly schedule. If you miss by more than 4 days, skip the missed dose and take the next one on schedule. Don't double up. Missing one dose in a microdose protocol delays your titration timeline by one week but doesn't require restarting from the beginning.

How do I know if microdosing is working? Microdosing "works" if it allows you to reach therapeutic doses (5 mg or higher) without discontinuing due to side effects. The goal isn't to stay at microdoses permanently. Track your weight weekly and GI symptoms daily. If you're losing 0.5 to 1% of body weight per week with tolerable side effects, you're on track.

Should I microdose if I'm under 50 kg? Patients under 50 kg may reach therapeutic GLP-1 receptor occupancy at lower absolute doses than heavier patients. Starting at 1 mg instead of 2.5 mg is reasonable, but this should be a clinical decision based on your provider's assessment, not a self-directed choice.

Can I stay on a microdose long-term instead of escalating? Staying at 1 mg or 1.5 mg long-term is suboptimal for most patients. Tirzepatide's weight-loss efficacy is dose-dependent, and clinical trial data shows significantly better outcomes at 10 mg and 15 mg than at lower doses. If you're tolerating a microdose well, the clinical recommendation is usually to escalate until you either reach your weight goal or hit intolerable side effects.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Chen L et al. Early Discontinuation Rates and Predictors in GLP-1 Receptor Agonist Therapy. Obesity Medicine. 2024.
3. Martinez R et al. Cross-Tolerance and Sequential GLP-1 Agonist Therapy. Diabetes, Obesity and Metabolism. 2025.
4. Li W et al. Dose-Dependent Safety Profile of Tirzepatide: A Meta-Analysis. Diabetes Care. 2025.
5. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes: State-of-the-Art. Molecular Metabolism. 2021.
6. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
7. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes. Lancet. 2021.
8. Ludvik B et al. Once-Weekly Tirzepatide versus Once-Daily Insulin Degludec as Add-on to Metformin. Lancet Diabetes & Endocrinology. 2021.
9. United States Pharmacopeia. Chapter 797: Pharmaceutical Compounding - Sterile Preparations. 2024.
10. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
11. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Advances in Therapy. 2018.
12. Aroda VR et al. Comparative Efficacy, Safety, and Cardiovascular Outcomes with Once-Weekly Subcutaneous Semaglutide. Circulation. 2019.
13. Garvey WT et al. Two-year Effects of Semaglutide in Adults with Overweight or Obesity. Nature Medicine. 2022.
14. Smits MM et al. GLP-1 Based Therapies: Clinical Implications for Gastric Emptying. Diabetes, Obesity and Metabolism. 2016.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.